Journals / Androloji Bülteni / 2022 / Cilt: 24 - Sayı: 4

Usage of PSA in patients with benign prostatic hyperplasia

Benign prostat hiperplazisi olan hastalarda PSA kullanımı

Pages
273–277
Publication Date
2023-11-27
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review article, the use of serum PSA in the diagnosis of BPH, in the prediction of Benign Prostatic Hyperplasia (BPH) progression, in the selection of BPH medical treatment, and in the follow-up of patients under medical treatment is described.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Prostate Specific Antigen (PSA) is a glycoprotein secreted from prostate acini.
📊
Key Findings & Data:Although PSA is generally considered a test used for prostate cancer (PCa), PSA is an organ-specific marker, not a disease-specific marker.
💡
Conclusion & Impact:In this review article, the use of serum PSA in the diagnosis of BPH, in the prediction of Benign Prostatic Hyperplasia (BPH) progression, in the selection of BPH medical treatment, and in the follow-up of patients under medical treatment is described.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Prostate Specific Antigen (PSA) is a glycoprotein secreted from prostate acini. Although PSA is generally considered a test used for prostate cancer (PCa), PSA is an organ-specific marker, not a disease-specific marker. It should not be forgotten that serum PSA level is important in the diagnosis of prostate cancer as well as in other benign conditions of the prostate. In this review article, the use of serum PSA in the diagnosis of BPH, in the prediction of Benign Prostatic Hyperplasia (BPH) progression, in the selection of BPH medical treatment, and in the follow-up of patients under medical treatment is described.

Özet

Prostat Spesifik Antijen (PSA), prostat asinilerinden salgılanan bir glikoproteindir. Prostat spesifik antijen sıklıkla prostat kanseri (PKa) için kullanılan bir test olarak düşünülmesine karşın PSA hastalık özel bir belirteç değildir, organ özel bir belirteçtir. Serum PSA düzeyinin kesinlikle prostat kanseri tanısında önemli olduğu kadar prostatın diğer benign durumlarında da önemli olduğu unutulmamalıdır. Bu derleme makalede serum PSA düzeyinin Benign Prostat Hiperplazisi (BPH) tanısında, BPH progresyonunun öngörülmesinde, BPH medikal tedavisini seçiminde ve medikal tedavi altındaki hastaların takibindeki kullanımı anlatılmaktadır.

🔖

Cite This Article

ATAN, A. (2023). Usage of PSA in patients with benign prostatic hyperplasia. Androloji Bülteni, Cilt: 24 - Sayı: 4, 273–277. https://doi.org/10.24898/tandro.2022.93653

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979;17:159–63.
  2. Venderbros LDF, Roobol MJ. PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making. Asian J Androl. 2011;13:219–24. [CrossRef] 3. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–16. [CrossRef] 4. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156– 61. [CrossRef] 5. Mettlin C, Murhpy GP, Lee F, Littrup PJ, Chesley A, Babaian R, et al. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Cancer. 1993;72:1701–8. [CrossRef] 6. Obort AS, Ajadi MB, Akinloye O. Prostate-specific antigen: any successor in sight? Rev Urol. 2013;15:97–107. https://pubmed. ncbi.nlm.nih.gov/24223021/ 7. van Renterghem K, van Koeveringe G, Achten R, van Kerrebroeck P. A new algorithm in patients with elevated and/or rising prostatespecific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies. Int Urol Nephrol. 2010;42:29– 38. [CrossRef] 8. Gjertson CK, Albertsen PC. Use and assessment of PSA in prostate cancer. Med Clin North Am. 2011;95:191–200. [CrossRef] 9. Greene KL, Albertsen PC, Babaian R, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement:2009 update. J Urol. 2013;189:S2–11. [CrossRef] 10. Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology. 1993;42:276–82. [CrossRef] 11. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level 12. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–9. [CrossRef] 13. Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, Rieken M, et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS) -Update March 2022. https://d56bochluxqn